Está aquí: Home > Therapeutics (antiguo) > Combined Treatment of Tourette Syndrome with Delta-9-THC and Dopamine Receptor Antagonists

J Cannabis Ther 2002(3/4):143-152

Tourette Syndrome

Combined Treatment of Tourette Syndrome with Delta-9-THC and Dopamine Receptor Antagonists

Author
KR Müller-Vahl, U Schneider, HM Emrich

Abstract
Animal studies suggest that cannabinoid receptor agonists might enhance the effect of dopamine receptor antagonists (neuroleptics, NL) in hyperkinetic movement disorders. In Tourette syndrome, NL are the most effective drugs for the treatment of tics. Recent clinical trials demonstrated that delta-9-tetrahydrocannabinol (delta-9-THC) also produces a tic-suppressing effect. In this single case study in a 24 years old female suffering from TS with extreme tics, it is suggested for the first time that delta-9-THC may be useful in augmenting the pharmacological response to atypical NL such as amisulpride and risperidone in TS patients. No serious adverse reactions occurred. Controlled studies are necessary to confirm this initial report.


Keywords
Tourette syndrome, tics, cannabis, THC, amisulpride, neuroleptics

Versión PDF del texto completo ]

Eventos en línea 2020

Toda la información sobre los eventos en línea de la IACM, incluidos los vídeos gratuitos de los seminarios web con subtítulos en español, puede encontrarse aquí.

Conferencia 2022

 La 12ª Conferencia de la IACM sobre Cannabinoides en Medicina se celebrará los días 20 y 21 de octubre de 2022 junto con la SSCM suiza en Basilea/Suiza.

Members only

Regular members can sign up for the new member area of the IACM to access exclusive content.

You need to become a regular member of the IACM to access the new member area.

IACM on Twitter

Follow us on twitter @IACM_Bulletin where you can send us inquiries and receive updates on research studies and news articles.